Colorectal Cancer

>

Latest News

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.
Nivolumab/Ipilimumab Earns CHMP Recommendation for Colorectal Cancer

November 18th 2024

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.
FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC

October 23rd 2024

Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.
FDA Approves Noninvasive Stool DNA Test for Colorectal Cancer Screening

October 4th 2024

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

October 3rd 2024

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC

September 25th 2024